A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 232,800 shares of ENTA stock, worth $2.64 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
232,800
Previous 282,000 17.45%
Holding current value
$2.64 Million
Previous $4.92 Million 38.68%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$11.43 - $17.02 $562,356 - $837,384
-49,200 Reduced 17.45%
232,800 $3.02 Million
Q1 2024

May 15, 2024

SELL
$10.08 - $17.46 $88,704 - $153,648
-8,800 Reduced 3.03%
282,000 $4.92 Million
Q4 2023

Feb 14, 2024

BUY
$8.18 - $10.78 $1.3 Million - $1.71 Million
158,400 Added 119.64%
290,800 $2.74 Million
Q3 2023

Nov 14, 2023

BUY
$11.09 - $22.13 $1.17 Million - $2.34 Million
105,900 Added 399.62%
132,400 $1.48 Million
Q2 2023

Aug 14, 2023

SELL
$20.68 - $39.85 $200,596 - $386,545
-9,700 Reduced 26.8%
26,500 $567,000
Q1 2023

May 15, 2023

SELL
$38.82 - $54.59 $791,928 - $1.11 Million
-20,400 Reduced 36.04%
36,200 $1.46 Million
Q4 2022

Feb 14, 2023

BUY
$40.77 - $53.73 $403,623 - $531,927
9,900 Added 21.2%
56,600 $2.63 Million
Q3 2022

Nov 14, 2022

SELL
$48.29 - $71.27 $526,361 - $776,843
-10,900 Reduced 18.92%
46,700 $2.42 Million
Q2 2022

Aug 15, 2022

SELL
$38.13 - $76.93 $91,512 - $184,632
-2,400 Reduced 4.0%
57,600 $2.72 Million
Q1 2022

May 16, 2022

SELL
$56.06 - $74.11 $2.13 Million - $2.82 Million
-38,000 Reduced 38.78%
60,000 $4.27 Million
Q4 2021

Feb 14, 2022

BUY
$60.19 - $97.37 $975,078 - $1.58 Million
16,200 Added 19.8%
98,000 $7.33 Million
Q3 2021

Nov 15, 2021

BUY
$41.02 - $58.65 $258,426 - $369,495
6,300 Added 8.34%
81,800 $4.65 Million
Q2 2021

Aug 16, 2021

SELL
$43.76 - $53.11 $218,800 - $265,550
-5,000 Reduced 6.21%
75,500 $3.32 Million
Q1 2021

May 17, 2021

SELL
$41.69 - $54.95 $429,407 - $565,985
-10,300 Reduced 11.34%
80,500 $3.97 Million
Q4 2020

Feb 16, 2021

BUY
$41.16 - $47.47 $465,107 - $536,411
11,300 Added 14.21%
90,800 $3.82 Million
Q3 2020

Nov 16, 2020

SELL
$43.36 - $53.53 $472,624 - $583,477
-10,900 Reduced 12.06%
79,500 $3.64 Million
Q2 2020

Aug 14, 2020

SELL
$46.37 - $57.58 $78,829 - $97,886
-1,700 Reduced 1.85%
90,400 $4.54 Million
Q1 2020

May 15, 2020

BUY
$40.22 - $62.0 $1.61 Million - $2.48 Million
40,000 Added 76.78%
92,100 $4.74 Million
Q4 2019

Feb 14, 2020

BUY
$57.95 - $66.61 $1.43 Million - $1.64 Million
24,600 Added 89.45%
52,100 $3.22 Million
Q3 2019

Nov 14, 2019

SELL
$60.08 - $88.17 $42,056 - $61,719
-700 Reduced 2.48%
27,500 $1.65 Million
Q2 2019

Aug 14, 2019

BUY
$81.3 - $97.35 $1.43 Million - $1.71 Million
17,600 Added 166.04%
28,200 $2.38 Million
Q4 2018

Feb 14, 2019

SELL
$65.41 - $84.65 $183,148 - $237,020
-2,800 Reduced 20.9%
10,600 $751,000
Q3 2018

Nov 14, 2018

SELL
$85.46 - $126.37 $2.92 Million - $4.32 Million
-34,200 Reduced 71.85%
13,400 $1.15 Million
Q2 2018

Aug 14, 2018

BUY
$81.85 - $120.51 $466,544 - $686,907
5,700 Added 13.6%
47,600 $5.52 Million
Q1 2018

May 15, 2018

BUY
$57.91 - $92.15 $509,607 - $810,920
8,800 Added 26.59%
41,900 $3.39 Million
Q4 2017

Feb 14, 2018

BUY
$45.65 - $59.37 $958,650 - $1.25 Million
21,000 Added 173.55%
33,100 $1.94 Million
Q3 2017

Nov 14, 2017

BUY
$37.91 - $46.8 $458,710 - $566,280
12,100
12,100 $566,000

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $235M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.